Semaglutide has demonstrated glycemic, weight and cardiac benefits in those with and without type 2 diabetes (T2D) 16,17,18
The needles used are extremely thin and short, designed to reach only the fatty tissue just beneath the skin rather than the muscle
However, a published expert review of the Phase 2 data in Expert Opinion on Investigational Drugs (2023) noted: "Heart rate was increased by up to 6.7 beats/min by retatrutide, which may be detrimental and offset some of the benefits of weight loss" particularly for patients with cardiovascular comorbidities
It is because those areas are commonly used for subcutaneous injections and are easier to inspect, rotate, and avoid when irritated
doi: 10.1530/erc-11-0065 68
Morbi accumsan ipsum velit